Cagrilintide – 10mg – Research Spray Kit

Researchers employ Cagrilintide in laboratory models to investigate its molecular interactions and behavior under controlled conditions:

• In vitro assays: Biochemical and cell culture experiments to study peptide stability, receptor binding, and molecular interactions.
• In vivo models: Animal-based studies designed to explore peptide activity in whole biological systems.
• Pharmacokinetic-style evaluations: Laboratory setups assessing absorption, dispersion, and peptide stability in solution.
• Formulation and delivery testing: Comparative studies using the spray system to evaluate alternative administration methods and bioavailability.

• Metabolic signaling research: Laboratory investigations into peptide interactions with receptors in controlled metabolic models.
• Endocrinology models: Experimental studies on peptide behavior in hormone-related laboratory systems.
• Obesity and metabolic regulation studies: Research using controlled models to examine pathways related to energy balance and receptor activity.
• Molecular biology applications: Studies examining peptide-protein interactions, receptor binding, and signaling mechanisms.
• Pharmacological research: Laboratory analyses of peptide stability, dispersion, and solution behavior using spray-based delivery.

The Cagrilintide 10mg Research Spray Kit provides a lyophilized peptide for controlled laboratory investigation. Its precision spray delivery system enables the study of alternative administration pathways, solution stability, and absorption efficiency. The kit supports a range of experimental studies, including metabolic signaling, endocrinology, molecular biology, and pharmacological research.

1. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021 May 8;397(10286):1736-1748. doi: 10.1016/S0140-6736(21)00845-X. Epub 2021 Apr 22. PMID: 33894838.
2. Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021 Dec 11;398(10317):2160-2172. doi: 10.1016/S0140-6736(21)01751-7. Epub 2021 Nov 16. PMID: 34798060.
3. Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023 Aug 26;402(10403):720-730. doi: 10.1016/S0140-6736(23)01163-7. Epub 2023 Jun 23. PMID: 37364590.
4. Simone A. Melander, Anna Katri, Morten A. Karsdal, Kim Henriksen, Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin, European Journal of Pharmacology, Volume 938, 2023, 175397, ISSN 0014-2999, https://doi.org/10.1016/j.ejphar.2022.175397.
5. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015 Sep;58(18):7370-7380. DOI: 10.1021/acs.jmedchem.5b00726. PMID: 26308095.